Severe acute respiratory virus syndrome 2 (SARS-CoV-2) has led to a worldwide pandemic.
Early studies in solid organ transplant (SOT) recipients suggested a wide variety of …

Knowledge on SARS-CoV-2 infection and its resultant COVID-19 in liver diseases has
rapidly increased during the pandemic. Hereby, we review COVID-19 liver manifestations …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

In the absence of effective countermeasures, human convalescent plasma has been widely
used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel …

Major changes have occurred in therapeutics for coronavirus-19 (COVID-19) infection over
the past 12–18 mo, most notably in early outpatient therapy. In most cases, solid organ …

Background: The COVID-19 pandemic, caused by a novel coronavirus termed SARS-CoV-2,
has spread quickly worldwide. Convalescent plasma (CP) obtained from patients following …

Background. Few reports have focused on newer coronavirus disease 2019 (COVID-19)
therapies (remdesivir, dexamethasone, and convalescent plasma) in solid organ transplant …

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) arose in December 2019
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …

As in the general population with coronavirus 2019 (COVID-19) infection, therapeutic
interventions in solid organ transplant (SOT) recipients have evolved over time. The …

In the absence of effective countermeasures, human convalescent plasma has been widely
used to treat severe acute respiratory syndrome coronavirus 2 including among patients with …